➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
AstraZeneca
Harvard Business School
McKinsey
Mallinckrodt

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,987,463

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,987,463 protect, and when does it expire?

Patent 8,987,463 protects BEVYXXA and is included in one NDA.

This patent has twelve patent family members in nine countries.

Summary for Patent: 8,987,463
Title:Methods of synthesizing factor Xa inhibitors
Abstract: Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof. ##STR00001##
Inventor(s): Pandey; Anjali (Fremont, CA), Leitao; Emilia P. T. (Lisbon, PT), Rato; Jose (Lisbon, PT), Song; Zhiguo Jake (Edison, NJ)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA) Portola Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:13/757,483
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 8,987,463

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,987,463

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 079491   Start Trial
Canada 2784904   Start Trial
China 102762538   Start Trial
China 104774176   Start Trial
European Patent Office 2513058   Start Trial
Spain 2610145   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Baxter
Mallinckrodt
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.